The treatment of Alzheimer disease has entered a new era, with a number of disease-modifying anti-amyloid-β therapies reaching the market in the past few years. Here we discuss the newest advances from phase III trials of solanezumab and donanemab.
This is a preview of subscription content, log in via an institution to check access.
References
Haeberlein, S. B. et al. Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease. J. Prev. Alzheimers Dis. 9, 197–210 (2022).
van Dyck, C. H. et al. Lecanemab in early Alzheimer’s disease. N. Engl. J. Med. 388, 9–21 (2023).
Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease. JAMA 330, 512–527 (2023).
Sperling, R. A. et al. Trial of solanezumab in preclinical Alzheimer’s disease. N. Engl. J. Med. https://doi.org/10.1056/nejmoa2305032 (2023).
Honig, L. S. et al. Trial of solanezumab for mild dementia due to Alzheimer’s disease. N. Engl. J. Med. 378, 321–330 (2018).
Sperling, R. A. et al. Anti-amyloid treatment in asymptomatic Alzheimer’s disease (A4) and longitudinal evaluation of amyloid risk and neurodegeneration (LEARN) study longitudinal results. In Alzheimer’s Association International Conference, available online at https://a4study.org/study-results/ (2023).
Donohue, M. C. et al. Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. J. Am. Med. Assoc. 317, 2305–2316 (2017).
Jutten, R. J. et al. Finding treatment effects in Alzheimer trials in the face of disease progression heterogeneity. Neurology 96, e2673–e2684 (2021).
Flier, W. M. van der, Vugt, M. E. de, Smets, E. M. A., Blom, M. & Teunissen, C. E. Towards a future where Alzheimer’s disease pathology is stopped before the onset of dementia. Nat. Aging 3, 494–505 (2023).
Tijms, B. M. et al. Large-scale cerebrospinal fluid proteomic analysis in Alzheimer’s disease patients reveals five molecular subtypes with distinct genetic risk profiles. Preprint at medRxiv https://doi.org/10.1101/2023.05.10.23289793 (2023).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Research programmes of W.M.v.d.F. have been funded by ZonMW, NWO, EU-JPND, Alzheimer Nederland, Hersenstichting CardioVascular Onderzoek Nederland, Health~Holland, Topsector Life Sciences & Health, stichting Dioraphte, Gieskes-Strijbis fonds, stichting Equilibrio, Edwin Bouw fonds, Pasman stichting, stichting Alzheimer & Neuropsychiatrie Foundation, Philips, Biogen MA Inc, Novartis-NL, Life-MI, AVID, Roche BV, Fujifilm, Eisai, Combinostics. W.M.v.d.F. holds the Pasman chair. W.M.v.d.F. is recipient of ABOARD, which is a public–private partnership receiving funding from ZonMW (#73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). W.M.v.d.F. has been an invited speaker at Biogen MA Inc, Danone, Eisai, WebMD Neurology (Medscape), NovoNordisk, Springer Healthcare, NovoNordisk, European Brain Council. W.M.d.v.F. is consultant to Oxford Health Policy Forum CIC, Roche, Biogen MA Inc, and Eisai. W.M.v.d.F. participated in advisory boards of Biogen MA Inc, Roche, and Eli Lilly. All funding is paid to her institution. W.M.v.d.F. is a member of the steering committee of PAVE, and Think Brain Health. W.M.v.d.F. was associate editor of Alzheimer’s Research & Therapy in 2020–2021. W.M.v.d.F. is an associate editor at Brain. B.M.T. declares no competing interests.
Rights and permissions
About this article
Cite this article
van der Flier, W.M., Tijms, B.M. Treatments for AD: towards the right target at the right time. Nat Rev Neurol 19, 581–582 (2023). https://doi.org/10.1038/s41582-023-00869-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41582-023-00869-0
- Springer Nature Limited